Drugs / ATX-MS-1467
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01097668 | Mar 2010 → Jul 2013 | relapsing-remitting multiple sclerosis | Apitope Technology (Bristol) Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01973491 | Feb 2014 → Apr 2016 | multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATX-MS-1467 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01097668 ↗ |
| Known as | MSC2358825A | “An Open-label, One-arm, Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 (MSC2358825A) and Its Effect on Immune Tolerance in Subjects With Relapsing Multiple Sclerosis” NCT01973491 ↗ |
| Action | Activate | “IL-10 Inducer” NCT01973491 ↗ |